DexCom, Inc. announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system (HCL) the Omnipod 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), for an easier diabetes management experience. In the Netherlands, 100,000 people have type 1 diabetes, with an estimated 10,000 children affected, making it the most common autoimmune disease among children after asthma. Type 1 diabetes can be challenging for anyone to manage and live with, but for children with Type 1, and their families, everyday activities such as exercising, eating, and swimming can be even more challenging.

The Omnipod 5 tubeless insulin pump integrated with the Dexcom G6 CGM can simplify their lives by offering easier diabetes management whilst allowing families, friends, and carers to remotely check glucose levels with the unique to Dexcom ?Follow? app||. Research published in Diabetes Care shows that use of this Hybrid Closed Loop system (HCL) significantly increased time in range (+11.5%) and reduced HbA1c and time in hypoglycemia (<70 mg/dL) in very young children (aged 2 ?

5.9 years) with Type 1 diabetes. The same study also saw adult participants spend an additional 11.8% more time in range. These significant and clinically meaningful health outcomes are only proven when the Omnipod 5 HCL system is integrated with Dexcom CGM.

For adults and children with Type 1 diabetes, this new Dexcom G6 and Omnipod 5 hybrid closed loop system, is an important step in improving their diabetes management. The system is the first tubeless HCL in the Netherlands approved for children, offering discretion and freedom to move without concern about tubes snagging or being pulled out. However, perhaps of most interest to parents or caregivers is the, unique to Dexcom, ?Follow?

app that allows Dexcom CGM users to simultaneously connect to their Omnipod 5 pump whilst sharing their glucose data in real time with up to 10 followers, offering everyone a little more peace of mind||. Moreover, with Dexcom G6§, the on-body parts of the system have a high-level of water resistance, so exercising and playing in swimming pools, seas and lakes becomes much easier. Emphasising Dexcom?s position as a leader in integrating connected systems, Dexcom G6 was exclusively used in the clinical trials that led to the regulatory approval of Omnipod 5 in Europe, Canada, and the United States.

Dexcom offers users choice and flexibility when it comes to how they manage their diabetes and view glucose levels. For example, Dexcom CGM also links# with multiple insulin pumps, digital health apps, lifestyle devices such as Garmin and Apple. All these options give people with diabetes freedom in managing the disease and making the right choice for them when it comes to appropriate care.

Dexcom G6 is available for reimbursement in the Netherlands via health insurers for children (18 and under), pregnant women (Type 1 and Type 2), women trying for pregnancy, and Type 1 hypo unaware users.